Molbio Diagnostics Aims for ₹200 Crore IPO to Boost Growth

Molbio Diagnostics, a prominent player in the molecular diagnostics sector, is gearing up for an initial public offering (IPO) to raise ₹200 crore. The funds are earmarked for capital expenditures, a move seen as a strategic step to fuel the company's growth and technological advancements.

Reducing Promoter Stake

Alongside the fresh issue, Molbio Diagnostics plans an offer for sale amounting to ₹740 crore. This will effectively reduce the promoter group's stake from 46.6% to 43%. The company operates six manufacturing facilities in India and serves a global clientele across more than 90 countries. Its customer base includes government health programs, diagnostic laboratories, hospitals, and international healthcare organizations.

Financial Performance and Market Reach

Founded in 2000, Molbio Diagnostics has carved a niche in developing diagnostic solutions for both infectious and non-communicable diseases. The company’s 'Truenat' platform, a portable diagnostic system, has been pivotal in offering rapid and accurate test results, especially in resource-limited settings. The firm offers molecular testing solutions for over 30 diseases and has developed 43 diagnostic assays.

Financially, Molbio Diagnostics has demonstrated robust growth. Between FY24 and FY26, revenue from operations increased by 31.5% annually, reaching ₹1,445.7 crore, while net profit rose by 40.2% annually to ₹164.1 crore. The company’s EBITDA grew by 33.2% to ₹328.2 crore, with EBITDA margins improving from 22% in FY24 to 22.6% in FY26. In the last fiscal year, revenue and EBITDA saw year-on-year increases of 41.7% and 27.9%, respectively, while net profit grew by 18.4%.

Investment Considerations

With a significant portion of its revenue—approximately 74%—stemming from the sale of test kits, particularly those for tuberculosis, Molbio Diagnostics has a concentrated revenue stream. This concentration is reflected in its customer base, where top clients contribute over half of the revenue. The company’s valuation post-IPO suggests a price-earnings (P/E) multiple of up to 57, positioning it among other healthcare diagnostics firms like Poly Medicure and Dr. Lal PathLabs, which trade at P/E multiples between 54 and 81.

For investors with a high-risk tolerance, the IPO offers a potential opportunity for long-term growth, given the company’s strong financial performance and strategic global presence. However, the concentration of revenue sources remains a consideration for potential investors.